FLOW trial: difference between revisions

Diff·revision 9 → 10·00:53, 20 Jan 2025

Difference between revision 9 and revision 10 of FLOW trial. 11 lines changed; the page grew by 496 bytes.

Revision 9 — 07:50, 3 Jan 2025 SurpassSunniva (talk) close an unbalanced quotation mark 2,601 bytes ±0	Revision 10 — 00:53, 20 Jan 2025 PioneerPerdita (talk) state that the trial has reported but is not yet peer-reviewed 3,097 bytes +496
1	{{Infobox concept	1	{{Infobox concept
2	\| name = FLOW trial	2	\| name = FLOW trial
+		3	\| subtitle = Renal outcome trial
3	\| Drug = [[Semaglutide\|Semaglutide]] 1.0 mg weekly	4	\| Drug = [[Semaglutide\|Semaglutide]] 1.0 mg weekly
4	\| Population = Type 2 diabetes with chronic kidney disease	5	\| Population = Type 2 diabetes with chronic kidney disease
⋮		⋮
19		20
20	Early stopping for efficacy shortens follow-up and tends to produce effect estimates larger than the trial would have produced had it run to completion. This is a well-characterised property of stopping rules rather than a defect of any particular trial.{{r\|ich_e9}}	21	Early stopping for efficacy shortens follow-up and tends to produce effect estimates larger than the trial would have produced had it run to completion. This is a well-characterised property of stopping rules rather than a defect of any particular trial.{{r\|ich_e9}}
+		22
+		23	== Results ==
+		24	\| Endpoint \| Direction \|
+		25	\|---\|---\|
+		26	\| Primary kidney composite \| Reduced, HR 0.76 (0.66–0.88) \|
+		27	\| Annual eGFR slope \| Less steep decline on semaglutide \|
+		28	\| Major adverse cardiovascular events \| Reduced \|
+		29	\| Death from any cause \| Reduced \|
+		30
+		31	The estimated glomerular filtration rate slope is informative because it describes trajectory rather than a threshold crossing, and is less sensitive to the timing of individual events.{{r\|perkovic2024}}
21		32
22	== References ==	33	== References ==